Entries by Christian Kähler

Unlocking the treasure trove

The Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.

From Emissions to Solutions: “Best CO2 Utilisation 2025” Innovation Award

UP Catalyst, Far Eastern New Century Corporation, and Oxylus Energy were recognised at the “Best CO2 Utilisation 2025” Innovation Award for transforming carbon emissions into high-performance battery materials, sustainable plastics for footwear and textiles, and methanol fuel, marking major strides toward a renewable carbon future.

BioFlo 320: Moving from R&D to commercial manufacturing

Precise parameter control is the foundation for efficient bioprocessing and scale-up. However, identifying the ideal scale-up strategy can be a work-intensive and time-consuming task. Here, the BioFlo 320 bioprocess controller with its innovative Scale Up Assist and other features can help you simplifying your cell culture process and scale up to working volumes of up to 40 L.

,

ADC Applications Beyond Oncology

Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.

,

Fueling innovation with accessible mRNA products

Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing lead times, this partnership will support early-phase researchers and established commercial clients with cutting-edge mRNA products.